We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Advanced melanoma currently has a 5-year survival rate ...

Complete response rate was 37%, and post-hoc end point of objective response rate was 89%. HealthDay News — Patients with advanced desmoplastic melanoma have high response to single-agent ...

Patients with wild-type metastatic melanoma that progressed on frontline PD-1 inhibition had almost a 2-year median overall survival (OS) when treated with single-agent ipilimumab (Yervoy), a small ...

Trick-MCC: Final results from the proof-of-concept investigator-initiated study of combination therapy with anti–PD-1, anti–LAG-3, and anti–TIM-3 in participants with advanced or metastatic PD-(L)1 ...

Maintaining normal vitamin D levels may improve the efficacy of immunotherapy in patients with advanced melanoma, a new study suggests. The finding comes from a study of 200 patients with melanoma who ...

Neoadjuvant immunotherapy in clinical stage III melanoma: Real life experience in the community setting. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not ...

This is a randomized, multicenter, pivotal study designed to evaluate the efficacy and safety of IBI363 monotherapy versus pembrolizumab monotherapy in patients with unresectable, locally advanced or ...

SAN FRANCISCO, U.S. and SUZHOU, China, June 1, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (A) (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic indications approvals under EU ...

Data presented on September 17 at the 2025 Immunorad Conference PARIS and CAMBRIDGE, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a ...